riok-1 Antibody

What is RIOK-1 and what are its primary functions?

RIOK1 is an atypical serine/threonine kinase with a molecular mass of approximately 67 kDa that plays multiple critical cellular roles. It is primarily involved in the final steps of cytoplasmic maturation of the 40S ribosomal subunit and in processing 18S-E pre-rRNA to mature 18S rRNA . Despite containing a protein kinase domain, RIOK1 is proposed to act predominantly as an ATPase, with its catalytic activity regulating its dynamic association with the 40S subunit . Beyond ribosomal biogenesis, RIOK1 functions as an adapter protein by recruiting NCL/nucleolin to the PRMT5 complex for symmetrical methylation .

What are the recommended applications for RIOK-1 antibodies?

RIOK-1 antibodies have been validated for multiple applications in research settings:

How should RIOK-1 antibodies be stored and handled?

For optimal antibody performance, store RIOK-1 antibodies at 2-8°C . Avoid repeated freeze-thaw cycles as this may compromise antibody integrity. When handling for experiments, maintain cold chain practices and consider preparing small working aliquots to minimize degradation from repeated handling. Most commercial antibodies come with specific storage recommendations that should be strictly followed to maintain reagent performance.

How does RIOK-1 function differ between normal and cancer cells?

• In RAS-mutant cancer cells, RIOK1 becomes essential for proliferation and survival, while RAS wildtype cells (e.g., Caco-2) show less dependence on RIOK1

• RIOK1 activates NF-κB signaling and promotes cell cycle progression in cancer cells

• It regulates pro-invasive proteins like Metadherin and Stathmin1

• RIOK1 is significantly overexpressed in non-small cell lung cancer (NSCLC) tissues and correlates with advanced stage and poor prognosis

• RIOK1 depletion inhibits proliferation, migration, and invasion in NSCLC cells through effects on AKT, Cyclin B1, MMP2, and EMT pathways

These differential functions make RIOK1 a promising cancer-specific therapeutic target, particularly for RAS-driven cancers .

What epitopes should be targeted when selecting RIOK-1 antibodies for specific experiments?

The choice of epitope is critical for experimental success with RIOK-1 antibodies:

• For human-specific detection: Select antibodies recognizing unique human RIOK1 epitopes, which can distinguish human tumor cells from murine stroma in xenograft models

• For functional studies: Target antibodies against the kinase domain (which may be involved in both catalytic activity and protein-protein interactions)

• For cross-species studies: Choose antibodies targeting conserved regions if studying RIOK1 across different model organisms

• For protein interaction studies: Avoid antibodies targeting regions involved in protein-protein interactions to prevent interference with complex formation

Commercial antibodies typically target either synthetic peptides within human RIOK1 (aa 50-200) or C-terminal regions , each offering different experimental advantages.

How does RIOK-1 contribute to innate immune regulation?

Research in C. elegans has identified RIOK-1 as a novel innate immune suppressor that specifically regulates the p38 MAPK pathway . The suppression of riok-1 confers resistance to Aeromonas dhakensis infection, suggesting its role as an immune repressor . During bacterial infection, the p38 MAPK pathway activates, transcribing riok-1 expression via skn-1, and activated riok-1 subsequently downregulates the p38 MAPK pathway through a negative feedback loop .

This immune regulatory function appears to be evolutionarily significant, as studies of the riok-1 gene (Sj-riok-1) in the parasitic blood fluke Schistosoma japonicum also show involvement in host-parasite interactions . These findings suggest that antibodies targeting RIOK-1 could be valuable tools for studying innate immunity across different organisms.

What are the optimal conditions for using RIOK-1 antibodies in immunoprecipitation experiments?

For successful immunoprecipitation of RIOK1 and its associated complexes:

• Lysate preparation:

  • Use gentle lysis buffers (e.g., 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40 or 0.5% Triton X-100)

  • Include protease inhibitors and phosphatase inhibitors if studying phosphorylation status

  • Maintain cold temperatures (4°C) throughout the procedure

• Immunoprecipitation protocol:

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Use 2-5 μg of RIOK1 antibody per mg of protein lysate

  • Incubate antibody-lysate mixture overnight at 4°C with gentle rotation

  • Capture antibody-protein complexes with protein A/G beads for 1-2 hours

  • Wash thoroughly (at least 4-5 times) with buffer containing reduced detergent

This approach has been successful in identifying RIOK1 association with components of the 20S methylosome and pre-40S ribosomal subunits .

How can RIOK-1 knockdown experiments be designed and validated?

When designing RIOK-1 knockdown experiments:

• siRNA design:

  • Design multiple siRNAs targeting different regions of RIOK1 mRNA

  • Include scrambled siRNA controls

  • Consider using validated siRNA sequences from published studies

• Validation methods:

  • Western blot: Use RIOK1 antibodies at 1:1000 dilution to confirm protein reduction

  • qRT-PCR: Design primers specific to RIOK1 transcripts

  • Functional assays: Measure 40S ribosomal subunit maturation or cancer cell proliferation

• Expected outcomes:

  • In cancer cells: Reduced proliferation, migration, and invasion; increased sensitivity to chemotherapy agents like cisplatin

  • In normal cells: Defects in 40S ribosomal subunit maturation; accumulation of cytoplasmic pre-rRNA

Careful validation is critical as multiple studies have shown distinct phenotypes depending on cell type, particularly between RAS-mutant versus RAS-wildtype cells .

How can specificity issues with RIOK-1 antibodies be addressed?

To ensure antibody specificity:

• Validation techniques:

  • RIOK1 knockdown controls: Compare antibody signals in wildtype versus RIOK1-depleted samples

  • Overexpression controls: Test detection of ectopically expressed tagged RIOK1

  • Peptide competition assays: Pre-incubate antibody with immunizing peptide to block specific binding

  • Cross-reactivity assessment: Test antibody on samples from different species if working in model organisms

• Common specificity issues:

  • Cross-reactivity with other RIO kinase family members (RIOK2, RIOK3)

  • Non-specific binding in certain tissue types

  • Background issues in immunohistochemistry applications

• Mitigation strategies:

  • Optimize antibody dilution (typically starting with 1:100 for IHC/ICC and 1:1000 for WB)

  • Increase blocking time and washing steps

  • Consider alternative antibody clones if persistent issues occur

How do you differentiate between the roles of RIOK-1 in normal ribosome biogenesis versus cancer-promoting functions?

Differentiating RIOK1's dual roles requires careful experimental design:

• Functional readouts:

  • Ribosome biogenesis: Monitor pre-rRNA processing by Northern blot, ribosomal subunit profiles on sucrose gradients, and localization of pre-40S components like hNob1, hRio2, and hLtv1

  • Cancer-promoting functions: Assess cell proliferation, migration, invasion, and activation of cancer-associated pathways (AKT, NF-κB, EMT markers)

• Genetic approaches:

  • Compare wild-type RIOK1 with kinase-dead mutants (e.g., D324 mutation)

  • Assess differential effects in RAS-mutant versus RAS-wildtype cell lines

  • Analyze effects of RIOK1 depletion on cisplatin sensitivity

• Context-dependent analysis:

  • Study RIOK1 in different cellular compartments (cytoplasmic versus nuclear)

  • Examine RIOK1 expression across cancer progression stages

  • Identify differential binding partners in normal versus cancer cells

These approaches help distinguish RIOK1's fundamental cellular roles from its cancer-specific functions, providing insights for potential therapeutic targeting.

How might RIOK-1 antibodies be used to study immune modulation in different disease models?

RIOK-1 antibodies offer promising applications for studying immune modulation:

• Infection models:

  • Track RIOK1 expression changes during pathogen challenges

  • Correlate RIOK1 levels with p38 MAPK pathway activation

  • Study RIOK1's role in parasite-host interactions, as demonstrated in Schistosoma japonicum research

• Cancer immunology:

  • Investigate RIOK1's impact on tumor microenvironment

  • Analyze correlations between RIOK1 expression and immune cell infiltration

  • Study potential connections between RIOK1 and response to immunotherapies

• Methodological approaches:

  • Combine RIOK1 immunohistochemistry with immune cell markers in tissue sections

  • Use RIOK1 antibodies for flow cytometry to analyze expression in specific immune cell populations

  • Apply proximity ligation assays to study RIOK1 interactions with immune signaling components

These applications could reveal RIOK1 as a novel regulator at the intersection of cancer biology and immunology, building on findings from C. elegans models showing RIOK1's role as an immune suppressor .

What are the implications of RIOK-1's role in chemoresistance for cancer therapy research?

Recent research has uncovered RIOK1's significant contribution to chemoresistance:

• Experimental evidence:

  • RIOK1 depletion sensitizes NSCLC cells to cisplatin treatment

  • RIOK1 knockdown upregulates apoptotic markers including cleaved PARP and Caspase-3 in chemotherapy-treated cells

  • RIOK1 appears to maintain cancer cell survival when exposed to chemotherapeutic agents

• Potential mechanisms:

  • Regulation of pro-survival pathways (AKT signaling)

  • Influence on cell cycle progression via Cyclin B1

  • Modulation of apoptotic threshold

• Research applications:

  • Use RIOK1 antibodies to monitor expression changes during treatment response/resistance development

  • Screen for RIOK1 inhibitors as chemosensitizing agents

  • Explore RIOK1 as a predictive biomarker for chemotherapy response

These findings suggest that RIOK1-targeted therapies might enhance conventional chemotherapy efficacy, particularly in tumors with elevated RIOK1 expression like NSCLC .